Knight Therapeutics Boosts 2026 Revenue Guidance on Strong Q1 Performance
Event summary
- Knight Therapeutics reported Q1 2026 revenues of $148.4 million, a 69% year-over-year increase.
- Adjusted EBITDA rose 130% to $27.9 million, with net income reaching $13.2 million.
- The company raised its 2026 revenue guidance to $510–$525 million from $490–$510 million.
- Strategic product launches and portfolio acquisitions drove growth, particularly in Canada and Latin America.
- Knight repurchased 1.3 million common shares under its NCIB and acquired an Argentine manufacturing facility.
The big picture
Knight Therapeutics' strong Q1 2026 performance reflects its strategic focus on expanding its pharmaceutical portfolio through acquisitions and regulatory approvals. The company's ability to navigate hyperinflation in Argentina and currency volatility will be critical as it aims to double its business size from five years ago. Its raised revenue guidance underscores confidence in its commercialization strategy across Canada and Latin America.
What we're watching
- Regulatory Momentum
- The pace at which Knight secures additional regulatory approvals for products like Niktimvo® and Minjuvi® will determine its ability to sustain revenue growth.
- Portfolio Integration
- How effectively Knight integrates the Paladin and Sumitomo portfolios will impact its operational efficiency and market reach.
- Currency Volatility
- Fluctuations in Latin American currencies, particularly the Argentine peso, could affect reported earnings and financial guidance.
Related topics